With a large (and growing) number of New Zealanders undergoing cancer therapy, eyecare professionals should be cognisant of the ocular complications that can result from many of these treatments to ensure their timely and appropriate diagnosis and management. Although chemotherapy remains a mainstay of the medical management of cancer, the repertoire and use of newer targeted therapies also continues to expand. With more tumour-specific effects on cell signalling and growth, this article focuses on these targeted therapies and their effects on the ocular surface and anterior segment.
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
